Therapeutic effect of carvedilol combined with sacubitril-valsartan on heart failure with reduced ejection fraction in elderly patients
李帅,金爱莲,张凤巧,李路
DOI: https://doi.org/10.3760/cma.j.cn115689-20230221-01366
2023-01-01
Abstract:Objective:To investigate the effects of carvedilol combined with sacubitril-valsartan in the treatment of heart failure with reduced ejection fraction (HFrEF) in elderly patients.Methods:A total of 80 patients with HFrEF admitted to First People’s Hospital of Shangqiu from January 2021 to July 2022 were selected, and they were divided into control group and observation group according to randomized block method, with 40 cases in each group. The control group was treated with sacubitril-valsartan, and the observation group was treated with carvedilol combined with sacubitril-valsartan. The two groups were treated for 5 months continuously. The cardiac function assessing by heart rate (HR), cardiac output (CO), left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD), myocardial injury markers, including blood N-terminal B-type natriuretic peptide precursor (NT-proBNP), serum cystatin C (CysC) and galectin-3 (Gal-3), exercise tolerance assessing by 6-minute walking test (6MWT), and the levels of electrolytes were compared between the two groups before and after treatment.Results:After treatment, the CO, LVEF and 6MWT of the two groups were higher than those before treatment (all P<0.05), and the corresponding values of the observation group were higher than those of the control group ( P<0.05); after treatment the levels of HR, LVESD, LVEDD, NT-proBNP, CysC and Gal-3 in the two groups were lower than those before treatment, and the corresponding values in the observation group were lower than those in the control group ( P<0.05). There was no significant difference in levels of electrolytes between the two groups ( P>0.05). Conclusions:Carvedilol combined with sacubitril-valsartan has a significant effect in the treatment of HFrEF, which can effectively improve the cardiac function of patients, enhance exercise tolerance, reduce myocardial injury; and it is beneficial to the prognosis of patients.